Eszopiclone + Fluoxetine + Placebo
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Sleep Initiation and Maintenance Disorders
Conditions
Sleep Initiation and Maintenance Disorders, Depression
Trial Timeline
Oct 1, 2005 → Dec 1, 2008
NCT ID
NCT00247624About Eszopiclone + Fluoxetine + Placebo
Eszopiclone + Fluoxetine + Placebo is a approved stage product being developed by Sumitomo Pharma for Sleep Initiation and Maintenance Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00247624. Target conditions include Sleep Initiation and Maintenance Disorders, Depression.
What happened to similar drugs?
20 of 20 similar drugs in Sleep Initiation and Maintenance Disorders were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00247624 | Approved | Completed |
Competing Products
20 competing products in Sleep Initiation and Maintenance Disorders